In preclinical metabolic research, 5-Amino-1MQ and SLU-PP-332 represent two distinct molecular approaches to modulating cellular energy expenditure. While 5-Amino-1MQ targets nicotinamide N-methyltransferase (NNMT) to preserve NAD+ pools and enhance adipocyte bioenergetics, SLU-PP-332 acts as a synthetic estrogen-related receptor (ERR) agonist to drive mitochondrial biogenesis and oxidative muscle gene expression.
In preclinical metabolic research, 5-Amino-1MQ and SLU-PP-332 represent two distinct molecular approaches to modulating cellular energy expenditure. While 5-Amino-1MQ targets nicotinamide N-methyltransferase (NNMT) to preserve NAD+ pools and enhance adipocyte bioenergetics, SLU-PP-332 acts as a synthetic estrogen-related receptor (ERR) agonist to drive mitochondrial biogenesis and oxidative muscle gene expression.
In modern bioenergetic and metabolic research, investigators frequently explore small molecules capable of altering intracellular energy signaling without relying on classical hormonal or sympathomimetic cascades. Among these compounds, 5-Amino-1MQ and SLU-PP-332 have emerged as important pharmacological tools for evaluating mitochondrial function, lipid substrate oxidation, and cellular respiration.
While both agents are studied in the context of metabolic rate enhancement and tissue-specific nutrient utilization, their biochemical targets are entirely non-overlapping. 5-Amino-1MQ is a selective, membrane-permeable small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme predominantly expressed in white adipose tissue and liver. Conversely, SLU-PP-332 is a pan-agonist of the estrogen-related receptors (specifically ERRα, ERRβ, and ERRγ), a class of nuclear receptors that direct mitochondrial biogenesis and oxidative capacity in skeletal muscle and cardiac tissues.
Understanding the precise enzymatic pathways, binding kinetics, and target tissue selectivity of both compounds is essential for designing rigorous in vitro and rodent model experiments. Investigators comparing these agents can systematically assess how direct enzymatic blockade of NAD+ degradation contrasts with nuclear-receptor-driven transcription of oxidative machinery across our comprehensive collection of all research compounds.
Nicotinamide N-methyltransferase (NNMT) plays a critical role in cellular energy regulation by methylating nicotinamide (NAM) using S-adenosylmethionine (SAM) as a methyl donor. This enzymatic process yields N1-methylnicotinamide (MNAM) and S-adenosylhomocysteine (SAH). Because NAM serves as the direct precursor for the salvage synthesis of nicotinamide adenine dinucleotide (NAD+), high NNMT activity effectively depletes local NAD+ pools while consuming methyl groups vital for epigenomic histone methylation.
Preclinical models demonstrate that elevated NNMT expression in adipocytes correlates strongly with reduced metabolic efficiency, decreased basal respiration, and increased intracellular lipid accumulation. By administering 5-Amino-1MQ in cellular assays, researchers achieve competitive, reversible inhibition of NNMT. This inhibition halts the clearance of NAM, thereby driving increased flux through the NAD+ salvage pathway.
The resulting elevation in intracellular NAD+ availability leads to downstream activation of sirtuin enzymes (predominantly SIRT1 and SIRT3) and AMP-activated protein kinase (AMPK). In vitro data indicate that this signaling cascade upregulates basal metabolic rate in adipocytes, increases fatty acid oxidation, and suppresses lipid droplet expansion. Consequently, 5-Amino-1MQ serves as an essential probe for dissecting NAD+ homeostasis and fat-metabolism research without altering central adrenergic pathways.
SLU-PP-332 functions through an entirely distinct biological mechanism by directly targeting the estrogen-related receptor (ERR) family of nuclear transcription factors. Although structurally related to classical estrogen receptors, ERRs operate independently of endogenous estrogen ligands and serve as primary master regulators of mitochondrial biogenesis, oxidative phosphorylation (OXPHOS), and fatty acid transport.
In preclinical studies, SLU-PP-332 binds with high affinity to ERRα, ERRβ, and ERRγ, inducing a conformational shift that recruits coactivators such as PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). This transcriptional complex binds to specific estrogen receptor-related response elements (ERREs) across the nuclear genome, dramatically increasing the transcription of genes encoding electron transport chain (ETC) complexes, carnitine palmitoyltransferase 1 (CPT-1), and pyruvate dehydrogenase kinase 4 (PDK4).
Animal study data demonstrate that systemic administration of SLU-PP-332 in murine models results in a shift toward oxidative muscle fiber phenotypes (type I and type IIa fibers) characterized by heightened endurance capacity, increased mitochondrial mass, and enhanced basal energy expenditure. Crucially, these transcriptional changes occur without inducing cardiac hypertrophy or off-target reproductive organ stimulation, positioning SLU-PP-332 as a primary candidate for exercise-mimetic and aerobic adaptation research within the PX1 Research library.
Comparing 5-Amino-1MQ and SLU-PP-332 highlights how two distinct molecular classes can converge on the broader phenomenon of metabolic expenditure through entirely separate pathways. A fundamental difference lies in their primary target locations and enzymatic versus transcriptional mechanisms.
5-Amino-1MQ functions via direct catalytic enzyme blockade within the cytosol, primarily impacting white adipose tissue (WAT) and hepatic cells where NNMT activity is highest. Its primary physiological consequence in research assays is the conservation of cellular substrate (NAD+ and methyl groups) to reactivate dormant metabolic enzymes. In contrast, SLU-PP-332 operates in the cell nucleus, targeting nuclear receptors expressed predominantly in high-energy demands tissues such as skeletal muscle, cardiac tissue, and brown adipose tissue (BAT) to actively drive new protein synthesis and organelle assembly.
Researchers evaluating synergistic metabolic cascades often benchmark these small molecules against peptide-based metabolic regulators. For instance, studies exploring mitochondrial-derived peptides like MOTS-c research or growth hormone fragment analogues such as AOD 9604 examine distinct extracellular signal transduction pathways. Meanwhile, modern multi-receptor agonist research involving retatrutide mechanisms provides insight into systemic gut-brain axis signaling compared to the cell-autonomous mechanisms of 5-Amino-1MQ and SLU-PP-332.
In animal model research, both 5-Amino-1MQ and SLU-PP-332 have demonstrated substantial capacity to alter body composition and nutrient utilization profiles under high-fat diet conditions. However, the phenotypic outcomes observed in these studies reflect their distinct underlying mechanisms.
Rodent models receiving 5-Amino-1MQ show significant reductions in diet-induced adiposity, driven primarily by an increase in white fat cell energy expenditure and a reduction in adipocyte hypertrophy. In vitro assay data reveal that 5-Amino-1MQ-treated adipocytes display elevated oxygen consumption rates (OCR) and increased expression of thermogenic marker proteins like UCP-1 without necessitating physical exercise.
Conversely, rodent models administered SLU-PP-332 exhibit marked improvements in functional treadmill running distance and time, alongside enhanced glucose tolerance and insulin sensitivity. Metabolomic profiling of skeletal muscle tissue in these models reveals elevated levels of tricarboxylic acid (TCA) cycle intermediates and enhanced fatty acid β-oxidation enzymes. When researchers evaluate both compounds across multi-arm experimental designs, they can compare localized adipocyte metabolic remodeling (5-Amino-1MQ) against systemic, muscle-centric oxidative enhancement (SLU-PP-332).
Proper handling and solubilization are critical for maintaining the chemical integrity and biological activity of 5-Amino-1MQ and SLU-PP-332 in laboratory experiments. Both compounds are supplied as high-purity, crystalline solid powders intended strictly for non-human in vitro or preclinical animal research.
5-Amino-1MQ is a charged quinolinium salt that demonstrates moderate solubility in aqueous buffers such as phosphate-buffered saline (PBS, pH 7.4), but achieves maximum stability and concentration when dissolved in dimethyl sulfoxide (DMSO) or sterile laboratory-grade solvents. Stock solutions prepared in DMSO can typically be diluted into cell culture media for in vitro assays, provided final solvent concentrations remain below threshold toxicity limits (typically <0.1% v/v).
SLU-PP-332 is a hydrophobic organic compound requiring non-aqueous organic solvents for initial reconstitution. It demonstrates optimal solubility in high-purity DMSO, N-methyl-2-pyrrolidone (NMP), or ethanol. For animal model administration via intraperitoneal or subcutaneous injection in authorized research protocols, co-solvent vehicles comprising PEG-400, Tween-80, and saline are standardly utilized. Standard laboratory safety protocols—including working within a laminar flow hood, storing reconstituted aliquots at -80°C, and avoiding repeated freeze-thaw cycles—must be strictly observed.
To ensure reproducible and unconfounded data in bioenergetic experiments, researchers must utilize small molecules and peptides verified by rigorous, independent analytical testing. Low-purity compounds containing synthesis side-products, residual heavy metals, or residual solvents can alter cellular respiration assays and introduce false cytotoxicity.
PX1 Research enforces strict quality control standards across every single lot. Every batch of 5-Amino-1MQ and SLU-PP-332 undergoes reverse-phase high-performance liquid chromatography (RP-HPLC) to verify chemical purity exceeding 98%. High-resolution mass spectrometry (MS) is simultaneously performed to confirm exact molecular mass and structural identity, ensuring the absence of truncated synthesis intermediates or isomeric impurities.
Furthermore, compounds intended for cell culture or preclinical animal models are screened for bacterial endotoxins using chromogenic Limulus Amebocyte Lysate (LAL) assays. PX1 Research provides batch-specific, third-party Certificates of Analysis (COAs) accessible for every lot, supporting complete laboratory audit compliance for institutions establishing wholesale lab accounts.
Sourcing laboratory-grade small molecules requires selecting a supplier that adheres to established Good Manufacturing Practices (GMP) and operates under standardized ISO protocols. Synthesizing complex molecules like 5-Amino-1MQ and selective nuclear receptor agonists like SLU-PP-332 requires precise reaction kinetics and rigorous post-synthesis purification steps.
PX1 Research manufactures all compounds in state-of-the-art USA facilities. Operating within an ISO 17025 accredited laboratory environment, our synthesis teams utilize advanced automated peptide and small-molecule synthesizers paired with preparative HPLC purification columns. This ensures lot-to-lot consistency and chemical stability across scale.
By maintaining complete chain-of-custody tracking from raw reagent sourcing to final packaging, PX1 Research eliminates supply chain variability. Orders dispatch directly from our centralized distribution hubs in California and Arizona, utilizing expedited climate-controlled packaging to protect temperature-sensitive compounds during transit. Orders processed Monday through Friday before cut-off times qualify for same-day dispatch.
What is the primary biochemical distinction between 5-Amino-1MQ and SLU-PP-332?
5-Amino-1MQ is a small molecule enzymatic inhibitor of nicotinamide N-methyltransferase (NNMT) that works by preserving NAD+ and methyl donor pools in cells. SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ) that acts as a transcription factor activator to increase mitochondrial biogenesis.
Are 5-Amino-1MQ and SLU-PP-332 approved for human consumption or therapeutic use?
No. Both 5-Amino-1MQ and SLU-PP-332 are non-clinical research chemicals supplied strictly for laboratory, in vitro, and preclinical animal research use only. They are not intended for human or veterinary use, diagnosis, prevention, or therapy.
How does 5-Amino-1MQ alter cellular NAD+ levels in metabolic models?
NNMT normally methylates nicotinamide (NAM), clearing it from the salvage pathway. By inhibiting NNMT, 5-Amino-1MQ prevents NAM clearance, allowing cells to recycle NAM back into NAD+, which elevates sirtuin activity and stimulates metabolic rate in adipocyte models.
Which nuclear receptors are targeted by SLU-PP-332?
SLU-PP-332 targets the estrogen-related receptor (ERR) family, displaying high binding affinity for ERRα, ERRβ, and ERRγ. Its activation upregulates genes involved in mitochondrial oxidative phosphorylation and fatty acid transport.
What solvents are recommended for reconstituting 5-Amino-1MQ and SLU-PP-332 for in vitro assays?
Both compounds exhibit maximum solubility in dimethyl sulfoxide (DMSO). 5-Amino-1MQ can also be dissolved in select aqueous buffers at lower concentrations, whereas SLU-PP-332 requires organic solvents or co-solvent vehicle systems (e.g., DMSO/PEG-400/Tween-80 mixtures) for experimental prep.
How should lyophilized powders of 5-Amino-1MQ and SLU-PP-332 be stored?
Desiccated lyophilized powders should be stored at -20°C or -80°C away from direct light and moisture. Once reconstituted into solvent stock solutions, aliquots should be frozen at -80°C to prevent degradation from freeze-thaw cycles.
How does PX1 Research verify the purity of these compounds?
PX1 Research verifies each lot using reverse-phase high-performance liquid chromatography (RP-HPLC) to confirm purity over 98%, mass spectrometry (MS) for structural identification, and LAL assays to ensure endotoxin limits meet strict research standards.
Where can independent lab documentation (COA) for PX1 compounds be obtained?
Lot-specific Certificates of Analysis (COAs) generated by independent ISO 17025 accredited testing facilities are available directly through the PX1 Research platform by referencing the lot number on the product vial.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.